波士頓市長假日列車12/5 開進華埠

 

2021 CABA Annual Conference 12/4

2021 CABA Annual Conference

2021 CABA Annual Conference

New Era, New Horizon - Explore with Industry Pioneers and Leaders on the New Frontiers in Healthcare Innovation

Date: Dec 4, 2021

Time: 8:45 am - 12:15 pm EST

Agenda and Speaker Profile

This year’s annual conference of CABA will host a collection of industry pioneers and leaders from a diverse background in science and business. These speakers will share exciting stories and developments and offer their insights in fields that will continue to improve human health, including RNA therapeutics, cell therapies, gene editing, and new materials and methods in life sciences. We hope you will join us and explore the new frontiers in healthcare innovation.

 

9:00-9:25

Bo Ying, PhD

Founder and CEO, Abogen Biosciences

CABA President (2018-2019)

Bo Ying, Ph.D., is the founder and CEO of Suzhou Abogen Biosciences, dedicated to mRNA-based therapeutics with focus on immune-oncology as well as infectious diseases. Dr. Ying has decades of experiences in drug development, and he is also an expert in drug delivery system such as lipid nanoparticles. He has successfully led team in the process of drug product development, CMC, tech transfer and IND application for a variety of nucleic acid-based therapeutics. As with the ongoing Covid-19 pandemic, Abogen has developed an mRNA-based vaccine and received IND approval from National Center for Drug Evaluation in China. Currently the vaccine product is under phase III clinical trial. Prior to founding Abogen, Dr. Ying has worked as group leader with proven track record of success at different biotech companies in Boston such as Dicerna Pharmaceuticals, Moderna

Therapeutics and Trucode Gene Repair. Dr. Ying received his bachelor and master’s degrees from Fudan University and a Ph.D. degree from Northeastern University in Boston, USA.

 

9:25-9:50

Ke Xu, PhD

Founder, Chairman and CEO of VesiCURE

Extracellular Vesicles (EVs) for Drug Development and Delivery

Dr. Ke Xu is the founding CEO of VesiCURE Therapeutics. Dr. Xu received his Ph.D. in Genetics and Development from the University of Texas Southwestern Medical Center at Dallas. After that, he moved to Harvard University for his postdoc training with Drs. Andy McMahon and Doug Melton. In 2014, Dr. Xu joined Biogen to help set up neurodegenerative models using human iPSC and genome editing technologies. From 2016 and before VesiCURE, he worked at Codiak BioSciences, the first exosome therapeutic company in North America, focusing on discovery research and pipeline development.

 

9:50-10:15

Shi-Jiang (John) Lu, PhD, MPH

President and CEO of HebeCell Corporation

CAR NK Cells from 3D-iPSC Bioreactor: One Platform Endless Pipelines

Shi-Jiang (John) Lu, PhD, MPH, is the President and CEO of HebeCell Corporation, focusing on the development and clinical translation of regenerative medicine and cell therapy technologies, especially iPS-CAR-NK cells for the treatment of cancer, autoimmune and viral infectious diseases. Before establishing HebeCell, he was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which was acquired by Astellas Pharma in 2016. Dr. Lu is an expert in stem cell biology and regenerative medicine with 20 years of experiences. He has been conducting translational researches and discovery of novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. He also has extensive experience in process development and large-scale production of human PSC derivatives under defined conditions for clinical trials. Dr. Lu is the inventor of more than 20 patents in stem cell field: in an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, his patent application and citation ranked No. 7 and No. 5, respectively. In addition to stem cell research, Dr. Lu also has more than 10 year experiences in cancer research. Dr. Lu received his BS degree in Biochemistry from Wuhan University, MSc degree in Oncology/Pathophysiology from Peking Union Medical College, MPH degree in Molecular Toxicology/Environmental Sciences from Columbia University and PhD degree in Molecular Cancer Biology from the University of Toronto.

Therapeutics and Trucode Gene Repair. Dr. Ying received his bachelor and master’s degrees from Fudan University and a Ph.D. degree from Northeastern University in Boston, USA.

 

10:25-10:50

Ed Zhang, MBA

Co-founder and Interim CEO of Overland Pharmaceuticals, Venture Partner of Hillhouse Capital

Opportunities and Challenges for a Cross-border Cell Therapy NewCo.

Ed Zhang, MBA, serves as Co-founder and Interim CEO at Overland Pharmaceuticals, and is Venture Partner at Hillhouse Capital. Prior to Overland, Mr. Zhang was VP of Corporate Development at Boston Pharmaceuticals, representing a new biotech business model focused on translational clinical development. As part of its founding team, Mr. Zhang led corporate development and strategic initiatives including establishing partnerships with leading global pharma and biotech companies. Before joining Boston Pharma, Mr. Zhang headed Global Business Development for Sanofi’s Renal Strategic Unit, and was Director of Commercial Operations and Strategic Development at Genzyme before its acquisition by Sanofi. Mr. Zhang started his career as a medicinal chemist at Pharmacia & Upjohn and now brings over 18 years of biopharma industrial experience to Overland. Mr. Zhang holds an MBA from Kellogg School of Management at Northwestern University, an MS in chemistry from Binghamton University, and a BS from Nanjing University.

 

10:50-11:15

Eric von Hofe, PhD

President and COO of AffyImmune Therapeutics

Affinity Tune and Track CAR T Cell Technology for Solid Tumors

Eric von Hofe, Ph.D., has over 25 years of experience in biotechnology with a focus on cancer immunotherapy and technology development. Before joining AffyImmune Therapeutics, he led development efforts at Antigen Express advancing the clinical development of novel cancer immunotherapies. Prior to that he held positions of increasing responsibility at Millennium Pharmaceuticals aligning novel technology initiatives with genomics-based drug development objectives.

 

11:25-11:50

Tasuku Kitada, PhD

President and Head of R&D of Strand Therapeutics

Progamming mRNA for Cancer Immunotherapy

Dr. Tasuku Kitada is President and Head of R&D of Strand Therapeutics. He co-founded Strand and serves on its Board of Directors. Prior to Strand, Dr. Kitada was Senior Biotechnology Analyst at Candriam Investors Group, where he conducted due diligence for the company’s multi-billion-dollar biopharma public equity investment strategy. At Candriam, he focused on cell and gene therapy companies, and also covered numerous oncology companies. Currently, Dr. Kitada continues to serve Candriam Investors Group as an advisor. Prior to Candriam, Dr. Kitada was a researcher at the Synthetic Biology Center at MIT, where he became the first scientist to create synthetic gene circuits using synthetic mRNA. This was the first demonstration of post-transcriptional circuits that can be “wired” to create a variety of networks of increasing complexity, which enabled cell type specific expression as well as small-molecule based control of gene expression from synthetic mRNA. This important research led to publications in Science, Nature Biotechnology, and Nature Chemical Biology. The mRNA synthetic biology platform developed from this research has been exclusively licensed to Strand. Dr. Kitada holds a Ph.D. in Molecular Biology from the University of California, Los Angeles and a B.S. in Biophysics and Biochemistry from the University of Tokyo.

 

11:50-12:15

David Lebwohl, PhD

EVP and CMO of Intellia Therapeutics

CRISPR/Cas9 In Vivo Genome Editing for Transthyretin Amyloidosis: First Clinical Results

Dr. David Lebwohl is the Chief Medical Officer at Intellia Therapeutics, a genome editing company. Before Intellia, Dr. Lebwohl was the Chief Medical Officer at Semma Therapeutics Inc., and led drug development teams at Novartis Pharmaceuticals and Bristol Myers Squibb. At Novartis, he was Senior Vice President and Program Head, CAR-T Teams, responsible for the development of the breakthrough

therapy Kymriah® (tisagenlecleucel), approved for leukemia and lymphoma. Under his leadership,

the blockbuster drug Afinitor® (everolimus) was approved for metastatic breast, neuroendocrine, and

kidney cancer as well as the rare genetic disease tuberous sclerosis. Dr. Lebwohl received an AB in

Biochemical Sciences from Harvard College and an MD from Yale University. He completed his

fellowship training at Memorial Sloan Kettering Cancer Center in medical oncology and hematology

and his residency in internal medicine at the Brigham and Women’s Hospital in Boston.

线上会议

Zoom Meeting

12/04/2021

8:45 am - 12:15 pm EST

ID: 87540625701

Passcode: 718858

扫码或点击“阅读原文”

直达会议

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

昆士市聖誕節慶大遊行 好熱鬧

昆士市市長Tom Koch夫婦邀聖誕老人和市民提前慶祝節日來到。(圖片來源:昆士市政府)

    (Boston Orange整理編譯) 11月26日晚在興國街亞當斯公園前，就著璀璨燈光辦歌唱遊樂會，11月28日再來場聖誕大遊行。昆士市市長Tom Koch率隊策畫的這個歡慶節日週末好熱鬧，街上人頭湧湧，市民好開心。

迪士尼卡通人物穿梭現場，百老匯明星Liz Callaway獻唱，聖誕老人搭直昇機從天而降，昆士市自己的高中軍樂隊演奏，裝扮各有特色的花車列隊走過，吸引許多人26日晚擠到昆士市政府前的亞當斯公園，28日穿得像包成粽子，也要沿街擺出小板凳的欣賞這難得的，已睽違至少一年的假日景象。

去年的昆士市聖誕大遊行因為新冠病毒大流型取消了，今年好不容易又上了街頭，從興國街(Hancock)穿過Hannon公園路北上，一直遊行到北昆士高中。騎著摩托車的警察前導，吹風笛的警察緊跟其後。

參加遊行的軍樂隊中，北昆士高中的樂隊贏得大獎，新貝福(New Bedford)高中第二名，瑪莉完美之心學校(Immaculate Heart of Mary School)贏得第三名。

27號那天從直升機上從天而降，來到選美場(Pageant Field)的聖誕老人，在28日遊行這天，搭乘消防車參加遊行。

圍觀遊行的昆士市民，有許多人每年來看遊行，已連看了30年。一名去年搬到昆士市的居民，為自己今年看到遊行，感到很興奮，直說這可媲美紐奧良的嘉年華會了(Mardi Gras)。

昆士市聖誕節委員會主席Barry Welch也說，今年圍觀的人比往年更多。看來人們都很渴望生活恢復正常。他也很高興自己能籌畫推出這第68次的聖誕大遊行。

波士頓市長重新指派2名西裔學校委員會委員 任期至2024

MAYOR WU REAPPOINTS LORENA LOPERA AND RAFAELA POLANCO GARCÍA TO BOSTON SCHOOL COMMITTEE The two members will continue to serve Boston’s diverse public school district

 

 

BOSTON - Tuesday, November 30, 2021- Mayor Michelle Wu today announced the reappointments of Lorena Lopera and Rafaela Polanco García to the Boston School Committee, to serve the remainder of terms that end on January 1, 2024. Lopera is a Boston Public Schools (BPS) parent, Executive Director of Latinos for Education and current Boston School Committee member. Polanco García is also a BPS parent and current Boston School Committee member and serves as Director of Parent Engagement and Organizing at St. Stephen’s Youth Programs.  On July 22, 2021, former Mayor Kim Janey appointed Lopera and Polanco García to the Boston School Committee, whose terms were coterminous with Mayor Janey’s tenure. The Boston School Committee is the governing body of BPS. “Lorena Lopera and Rafaela Polanco García have served with dedication and urgency to ensure Boston Public Schools is connected to each one of our families,” said Mayor Michelle Wu. “I am excited and grateful to reappoint these passionate community leaders who have consistently advocated for equity, inclusion, and accessibility in our school system. They both will continue to work to support families, educators, and community members and advocate for the high-quality education our students deserve.” "I am excited to continue working with Ms. Lopera and Ms. Polanco García on our important work together as a School Committee," said Boston School Committee Chair Jeri Robinson. "They have each added great depth to our conversations as a Committee and I look forward to their continued engagement as we advance important policy issues with a deepened focus on family and community engagement where both Ms. Lopera and Ms. Polanco García have earned reputations for excellence in their fields." “I am honored to continue working in partnership with Ms. Lopera and Ms. Polanco García on behalf of our Boston Public Schools children,” said Boston Public Schools Superintendent Brenda Cassellius. "Working together with Mayor Wu and the entire Boston School Committee, we will continue taking bold action with urgency so that every student is set up to succeed in school and life." Lorena Lopera is a first generation immigrant from Colombia. She serves as Executive Director at Latinos for Education, New England, the first Latino-founded and led national organization dedicated solely to creating leadership pathways for Latinos in education. She is a veteran of local organizations focused on expanding educational access for Latinx youth and students of color, including Roxbury-based Sociedad Latina, Epiphany School, and La Vida, Inc., as well as national organizations such as BES, City Year the Posse Foundation. She currently serves on the board of EdVestors. Lorena is a proud BPS parent. "Thank you, Mayor Wu,” said Lopera. “I’m honored to continue to serve on the Boston School Committee. My educational experience and my experience as a Boston Public Schools parent will continue to guide my decisions on the committee. I look forward to working with families, educators and community members so that our school system is more equitable, responsive, and provides quality support for all of our children.” Rafaela Polanco García is an immigrant who lives in public housing in South Boston and has a background in law and bilingual advocacy. Her activism on behalf of the Latinx community in education includes working on the No on 2 campaign in 2016, helping to pass a sanctuary schools resolution, and passing the Student Opportunity Act. Since 2015, she has served as the Director of Parent Engagement and Organizing at St. Stephen’s Youth Programs in the South End. She is a BPS parent. “I am very excited about the opportunity to continue representing immigrants and English language learners,” said Polanco García. “Thank you to Mayor Michelle Wu for having this inclusive vision, reappointing me to this important position as a member of the Boston School Committee. I hope to continue promoting language access and to represent my community with dignity." The School Committee is responsible for: ·    Defining the vision, mission, and goals of the Boston Public Schools; ·    Establishing and monitoring the annual operating budget; ·    Hiring, managing, and evaluating the Superintendent; and ·    Setting and reviewing district policies and practices to support student achievement.   The School Committee meets approximately twice per month during the school year to adopt, review and modify policies and practices that support teaching, learning and improved student achievement. With the exception of executive sessions, Committee meetings are open to the public, feature public comment periods and are broadcast on Boston City TV.

 

 

###

 

LA ALCALDESA WU RENOMBRA A LORENA LOPERA Y RAFAELA POLANCO GARCÍA AL COMITÉ DE LAS ESCUELAS PÚBLICAS DE BOSTON Las dos miembros continuarán sirviendo al diverso distrito escolar público de Boston. BOSTON - Martes, 30 de noviembre de 2021- La alcaldesa Michelle Wu anunció hoy el renombramiento de Lorena Lopera y Rafaela Polanco García para el Comité Escolar de Boston, para cumplir el resto de los mandatos que terminan el 1 de enero de 2024. Lopera es madre de las Escuelas Públicas de Boston (BPS), Directora Ejecutiva de Latinos for Education y miembro actual del Comité Escolar de Boston. Polanco García también es madre de BPS y miembro actual del Comité Escolar de Boston, y se desempeña como Directora de Participación y Organización de los Padres en los Programas Juveniles de St. Stephen. El 22 de julio de 2021, la alcaldesa Kim Janey nombró a Lopera y Polanco García para el Comité Escolar de Boston, cuyos términos coincidían con el mandato de la alcaldesa Janey. El Comité Escolar de Boston es la asociación gobernante de BPS. “Lorena Lopera y Rafaela Polanco García han servido con dedicación y urgencia para asegurar que BPS esté conectado con cada una de nuestras familias”, dijo la alcaldesa Michelle Wu. “Estoy emocionada y agradecida de reapuntar a estas líderes de la comunidad apasionadas que han abogado constantemente por la equidad, la inclusión y la accesibilidad en nuestro sistema escolar. Las dos continuarán trabajando para apoyar a las familias, los educadores y los miembros de la comunidad y abogando por la educación de alta calidad que merecen nuestros estudiantes.” "Estoy emocionada de continuar trabajando con la Sra. Lopera y la Sra. Polanco García en nuestro importante trabajo juntas como Comité Escolar," dijo Jeri Robinson, presidente del Comité Escolar de Boston. "Cada una de ellas ha agregado una gran profundidad a nuestras conversaciones como Comité y espero su participación continue mientras avanzamos importantes cuestiones de política con un enfoque más profundo en la participación de la familia y la comunidad, donde la Sra. Lopera y la Sra. Polanco García se han ganado la reputación de excelencia en sus campos.” “Es un honor para mí continuar trabajando en conjunto con la Sra. Lopera y la Sra. Polanco García en nombre de nuestros niños de las Escuelas Públicas de Boston”, dijo la superintendente de las Escuelas Públicas de Boston, Brenda Cassellius. "Trabajando junto con la alcaldesa Wu y todo el Comité Escolar de Boston, continuaremos tomando medidas audaces con urgencia para que cada estudiante esté preparado para tener éxito en la escuela y en la vida." Lorena Lopera es una inmigrante de primera generación de Colombia. Se desempeña como Directora Ejecutiva en Latinos for Education, New England, la primera organización nacional liderada y fundada por latinos dedicada exclusivamente a crear caminos de liderazgo para los latinos en la educación. Es una veterana de organizaciones locales enfocadas en expandir el acceso educativo para jóvenes latinos y estudiantes de color, incluyendo Sociedad Latina en Roxbury, Epiphany School y La Vida, Inc., así como organizaciones nacionales como BES, City Year, y Posse Foundation. Actualmente sirve en la junta directiva de EdVestors. Lorena es una madre orgullosa de BPS. "Gracias, Alcaldesa Wu,” dijo Lopera. “Estoy honrada de poder seguir sirviendo en el Comité de las Escuelas Públicas de Boston. Mi experiencia educativa y mi experiencia como madre con un joven en las escuelas públicas de Boston seguirá guiando mis decisiones en el comité. Espero poder trabajar con familias, educadores, y miembros de la comunidad para que nuestro sistema educativo sea más equitativo, receptivo, y que provea apoyos calidosos para todos nuestros niños."  Rafaela Polanco García es una inmigrante que vive en vivienda pública en South Boston y tiene experiencia en derecho y defensa bilingüe. Su activismo en nombre de la comunidad latina en educación incluye trabajar en la campaña No en 2 en 2016, ayudar a aprobar una resolución de escuelas santuario y aprobar la Ley de Oportunidades Estudiantiles. Desde el 2015, se ha desempeñado como directora de participación y organización de los padres en los programas juveniles de St. Stephen en el South End. Ella es madre de BPS. “Estoy muy emocionada por la oportunidad de poder continuar representando a los inmigrantes y aprendices del idioma inglés,” dijo Polanco García. “Gracias a la Alcaldesa Michelle Wu por tener esa visión inclusiva, al designarme nuevamente en esta importante posición como lo es el ser miembro del Comité de las Escuelas Públicas de Boston. Espero seguir impulsando el acceso al idioma y representar dignamente a mi comunidad.” El Comité Escolar es responsable por: ·    Definir la visión, misión y metas de las Escuelas Públicas de Boston; ·    Establecer y monitorear el presupuesto operativo anual; ·    Contratar, administrar y evaluar al Superintendente; y ·    Establecer y revisar las polízas y prácticas del distrito para apoyar el rendimiento estudiantil. El Comité Escolar se reúne aproximadamente dos veces al mes durante el año escolar para adoptar, revisar y modificar polízas y prácticas que apoyan la enseñanza, el aprendizaje y la mejoría del rendimiento estudiantil. Con la excepción de las sesiones ejecutivas, las reuniones del Comité están abiertas al público, cuentan con períodos de comentarios públicos y se transmiten por Boston City TV.